Together, these results indicated that the PDE4 inhibitor roflumilast may be a potential approach to prevent or treat NAFLD-associated CKD by inhibiting PDE4D in the liver (Fig. 7). Here, PDE4A is linked to metabolic dysfunction-associated steatotic liver disease.